FGF23 has been reported to be increased in Chronic Kidney Disease (CKD) patients that also have elevated sclerostin-expressing osteocytes, highlighting the potential links between Wnt signaling and FGF23 (33, 34). This evidence concerns the gene SOST and chronic kidney disease.